MedTrace Logo

A Study to Assess Deucravacitinib Safety in Pregnancy

NCT07017699 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2025-06-12

No results posted yet for this study

Summary

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.

Conditions

  • Psoriasis (PsO)

Interventions

DRUG

Deucravacitinib

According to product label

DRUG

Other systemic treatments for PsO

According to product label

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2028-04-01
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017699 on ClinicalTrials.gov